Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Amortization of Deferred Charges: 2019-2024

Historic Amortization of Deferred Charges for Phathom Pharmaceuticals (PHAT) over the last 6 years, with Dec 2024 value amounting to $3.8 million.

  • Phathom Pharmaceuticals' Amortization of Deferred Charges rose 15.93% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year increase of 25.03%. This contributed to the annual value of $3.8 million for FY2024, which is 5.36% up from last year.
  • According to the latest figures from FY2024, Phathom Pharmaceuticals' Amortization of Deferred Charges is $3.8 million, which was up 5.36% from $3.6 million recorded in FY2023.
  • In the past 5 years, Phathom Pharmaceuticals' Amortization of Deferred Charges ranged from a high of $3.8 million in FY2024 and a low of $1.3 million during FY2020.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $3.6 million (2023), whereas its average is $3.6 million.
  • In the last 5 years, Phathom Pharmaceuticals' Amortization of Deferred Charges surged by 211.25% in 2020 and then dropped by 3.09% in 2022.
  • Yearly analysis of 5 years shows Phathom Pharmaceuticals' Amortization of Deferred Charges stood at $1.3 million in 2020, then surged by 182.40% to $3.6 million in 2021, then decreased by 3.09% to $3.5 million in 2022, then rose by 2.84% to $3.6 million in 2023, then increased by 5.36% to $3.8 million in 2024.